Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Equity Average (2016 - 2025)

Historic Equity Average for BioCorRx (BICX) over the last 16 years, with Q3 2025 value amounting to -$13.2 million.

  • BioCorRx's Equity Average fell 1445.76% to -$13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 1445.76%. This contributed to the annual value of -$1.2 million for FY2024, which is 23723.54% down from last year.
  • As of Q3 2025, BioCorRx's Equity Average stood at -$13.2 million, which was down 1445.76% from -$12.4 million recorded in Q2 2025.
  • In the past 5 years, BioCorRx's Equity Average registered a high of $346060.5 during Q4 2023, and its lowest value of -$13.2 million during Q3 2025.
  • For the 5-year period, BioCorRx's Equity Average averaged around -$7.7 million, with its median value being -$7.7 million (2022).
  • Its Equity Average has fluctuated over the past 5 years, first soared by 10449.37% in 2023, then crashed by 361939.2% in 2024.
  • BioCorRx's Equity Average (Quarter) stood at -$6.4 million in 2021, then decreased by 20.66% to -$7.7 million in 2022, then soared by 104.49% to $346060.5 in 2023, then tumbled by 3619.39% to -$12.2 million in 2024, then fell by 8.78% to -$13.2 million in 2025.
  • Its Equity Average was -$13.2 million in Q3 2025, compared to -$12.4 million in Q2 2025 and -$12.1 million in Q1 2025.